BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 12879484)

  • 1. Measuring chemotherapy-induced nausea and emesis.
    Martin CG; Rubenstein EB; Elting LS; Kim YJ; Osoba D
    Cancer; 2003 Aug; 98(3):645-55. PubMed ID: 12879484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres.
    O'Brien BJ; Rusthoven J; Rocchi A; Latreille J; Fine S; Vandenberg T; Laberge F
    CMAJ; 1993 Aug; 149(3):296-302. PubMed ID: 8339175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy.
    Decker GM; DeMeyer ES; Kisko DL
    J Support Oncol; 2006 Jan; 4(1):35-41, 52. PubMed ID: 16444851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.
    Bloechl-Daum B; Deuson RR; Mavros P; Hansen M; Herrstedt J
    J Clin Oncol; 2006 Sep; 24(27):4472-8. PubMed ID: 16983116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The development of a new QOL Questionnaire on chemotherapy - induced emesis and vomiting--investigation of reliability and validity. Group for Investigation of QOL Questionnaire for Anti-Emetics Used in Cancer Chemotherapy. Joint Research Group for Tropisetron Double-Blind Comparative study].
    Ishihara Y; Nukariya N; Kobayashi K; Yoneda S; Matsuda T; Yakushiji M; Yamakido M; Fukuoka M; Niitani H; Furue H
    Gan To Kagaku Ryoho; 1996 May; 23(6):745-55. PubMed ID: 8645026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parameters that influence the outcome of nausea and emesis in cisplatin based chemotherapy.
    Tsavaris N; Kosmas C; Mylonakis N; Bacoyiannis C; Kalergis G; Vadiaka M; Boulamatsis D; Iakovidis V; Kosmidis P
    Anticancer Res; 2000; 20(6C):4777-83. PubMed ID: 11205218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.
    Warr DG; Grunberg SM; Gralla RJ; Hesketh PJ; Roila F; Wit Rd; Carides AD; Taylor A; Evans JK; Horgan KJ
    Eur J Cancer; 2005 Jun; 41(9):1278-85. PubMed ID: 15939263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics.
    Grunberg SM; Deuson RR; Mavros P; Geling O; Hansen M; Cruciani G; Daniele B; De Pouvourville G; Rubenstein EB; Daugaard G
    Cancer; 2004 May; 100(10):2261-8. PubMed ID: 15139073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy.
    Bloch J; Rixe O; Meric JB; Delgado A; Khayat D
    Curr Med Res Opin; 2005 Nov; 21(11):1763-71. PubMed ID: 16307696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
    Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
    Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting.
    Voravud N; Sriuranpong V
    J Med Assoc Thai; 2005 Dec; 88(12):1790-6. PubMed ID: 16518975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Development of a Japanese version of the FLIE].
    Satou A; Yamazaki T; Nukariya N; Nakamachi M; Shimada K; Matsukawa M; Kurihara M
    Gan To Kagaku Ryoho; 2002 Feb; 29(2):281-91. PubMed ID: 11865635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life questionnaire cervical cancer module: EORTC QLQ-CX24.
    Greimel ER; Kuljanic Vlasic K; Waldenstrom AC; Duric VM; Jensen PT; Singer S; Chie W; Nordin A; Bjelic Radisic V; Wydra D;
    Cancer; 2006 Oct; 107(8):1812-22. PubMed ID: 16977652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of change of quality of life in terminally ill patients under cancer pain management using the EORTC Core Quality of Life Questionnaire (QLQ-C30) in a Korean sample.
    Park KU
    Oncology; 2008; 74 Suppl 1():7-12. PubMed ID: 18758191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study.
    Booth CM; Clemons M; Dranitsaris G; Joy A; Young S; Callaghan W; Trudeau M; Petrella T
    J Support Oncol; 2007 Sep; 5(8):374-80. PubMed ID: 17944146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute and delayed nausea and emesis control in pediatric oncology patients.
    Holdsworth MT; Raisch DW; Frost J
    Cancer; 2006 Feb; 106(4):931-40. PubMed ID: 16404740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The European Organization for Research and Treatment of Cancer QLQ-C30: an examination into the cultural validity and reliability of the Turkish version of the EORTC QLQ-C30.
    Guzelant A; Goksel T; Ozkok S; Tasbakan S; Aysan T; Bottomley A
    Eur J Cancer Care (Engl); 2004 May; 13(2):135-44. PubMed ID: 15115469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life analyses in a clinical trial of DPPE (tesmilifene) plus doxorubicin versus doxorubicin in patients with advanced or metastatic breast cancer: NCIC CTG Trial MA.19.
    Liu J; Tu D; Dancey J; Reyno L; Pritchard KI; Pater J; Seymour LK
    Breast Cancer Res Treat; 2006 Dec; 100(3):263-71. PubMed ID: 16823511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acupressure for chemotherapy-induced nausea and vomiting: a randomized clinical trial.
    Dibble SL; Luce J; Cooper BA; Israel J; Cohen M; Nussey B; Rugo H
    Oncol Nurs Forum; 2007 Jul; 34(4):813-20. PubMed ID: 17723973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.